Skip to main content
. Author manuscript; available in PMC: 2014 Dec 23.
Published in final edited form as: Nat Commun. 2014 Jun 23;5:4234. doi: 10.1038/ncomms5234

Figure 3. SUMO1 and CDK6 contributes to the tumorigenesis of neurospheres.

Figure 3

(a) Three neurospheres were transduced or not with the SUMO1 and CDK6 shRNAs as indicated (top) and tested by western blotting using SUMO1 and CDK6 antibodies. (b) The transduced neurospheres were examined by cell growth for 9 days (points: means; bar: SD; n = 6 from two independent experiments; *** P < 0.001; student’s t-test). (c) The transduced neurospheres were also examined by sphere formation assay with the numbers of neurospheres as indicated (left) (points: means; bar: SD; n = 6 from three independent experiments; *** P < 0.001; student’s t-test). (d,e) Coronal cerebral section (d) and microscopic section of hematoxylin and eosin (e) reveals the infiltrating glioblastoma in the right side of a mouse brain injected with the neurospheres expressing the control scrambled shRNA. (f,g) The glioblastoma xenograft was not observed in the mouse brain injected with the neurospheres expressing shRNA targeting SUMO1 (f) or CDK6 shRNA (g). (h) Kaplan-Meier curves show the survival of the mice intracranially injected with the neurospheres transduced with the indicated shRNA vectors (n = 6 for each group; *** P < 0.001; Log rank test).